FDA Advisers Weigh Composition of COVID Vaccines for 2026–2027
What’s happening
FDA vaccine advisers met to discuss which COVID-19 strain should be targeted in vaccines for the 2026–2027 season.
The discussion focused heavily on the XFG variant, which had become one of the most common COVID strains circulating in the United States. Advisers reviewed available data and debated whether manufacturers should update vaccines to better match the variant.
What’s changing / Business impact
The outcome could influence:
- future vaccine design
- manufacturing plans
- booster recommendations
- public health guidance
Companies such as Pfizer, Moderna, and Novavax may need to adjust production depending on the FDA's final recommendation.
Why this matters
COVID is no longer being treated as a one-time emergency. Instead, health officials are increasingly managing it the same way they manage seasonal flu.
Every year, experts examine which virus strains are spreading most widely and decide whether vaccines should be updated to provide better protection.
Some advisers also raised concerns that the U.S. now has less surveillance data than it did during the height of the pandemic, making it harder to predict which variants may dominate in the future.